Plasma-Derived Exosomal Survivin, a Plausible Biomarker for Early Detection of Prostate Cancer
暂无分享,去创建一个
Dan Mercola | Saied Mirshahidi | D. Mercola | Salma Khan | M. Lilly | David Turay | N. Wall | Nathan R. Wall | S. Mirshahidi | Michael B. Lilly | Jonathan R. Aspe | Salma Khan | Jessica M. S. Jutzy | Malyn May A. Valenzuela | David Turay | Arjun Ashok | Arjun Ashok | M. M. Valenzuela | J. Aspe
[1] John Calvin Reed,et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. , 1996, The American journal of pathology.
[2] D. Altieri. Survivin, versatile modulation of cell division and apoptosis in cancer , 2003, Oncogene.
[3] A. Vitiello,et al. Elevated expression of inhibitor of apoptosis proteins in prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] Joanne L Welton,et al. Can urinary exosomes act as treatment response markers in prostate cancer? , 2009, Journal of Translational Medicine.
[5] C. Roehrborn,et al. Survivin expression is associated with features of biologically aggressive prostate carcinoma , 2004, Cancer.
[6] M. Vidal,et al. Exosome Release Is Regulated by a Calcium-dependent Mechanism in K562 Cells* , 2003, Journal of Biological Chemistry.
[7] S. Shariat,et al. Les biomarqueurs émergents du diagnostic, du staging et du pronostic du cancer de la prostate , 2011 .
[8] B. Quah,et al. The immunogenicity of dendritic cell-derived exosomes. , 2005, Blood cells, molecules & diseases.
[9] B. Challacombe,et al. Is there a link between BPH and prostate cancer? , 2012, The Practitioner.
[10] M. Tsai,et al. Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter. , 1999, Molecular endocrinology.
[11] B. Kramer,et al. Screening for prostate cancer with PSA testing: current status and future directions. , 2011, Oncology.
[12] R. Johnstone,et al. Exosomes biological significance: A concise review. , 2006, Blood cells, molecules & diseases.
[13] H. Nagai,et al. Clinical Relevance of Survivin as a Biomarker in Neoplasms, Especially in Adult T-Cell Leukemias and Acute Leukemias , 2004, International journal of hematology.
[14] Lars Egevad,et al. Tumour markers in prostate cancer II: Diagnostic and prognostic cellular biomarkers , 2011, Acta oncologica.
[15] Josiah Ochieng,et al. Detachment of Breast Tumor Cells Induces Rapid Secretion of Exosomes Which Subsequently Mediate Cellular Adhesion and Spreading , 2011, PloS one.
[16] Salma Khan,et al. Survivin is released from cancer cells via exosomes , 2010, Apoptosis.
[17] Yiwei Li,et al. Regulation of gene expression and inhibition of experimental prostate cancer bone metastasis by dietary genistein. , 2004, Neoplasia.
[18] E. Klein,et al. Localized prostate cancer: radiation or surgery? , 2003, The Urologic clinics of North America.
[19] Zhiyong Guo,et al. Regulation of androgen receptor activity by tyrosine phosphorylation. , 2006, Cancer cell.
[20] G. Parmiani,et al. Tumour-released exosomes and their implications in cancer immunity , 2008, Cell Death and Differentiation.
[21] F. Castellino,et al. Exosomes released from macrophages infected with intracellular pathogens stimulate a proinflammatory response in vitro and in vivo. , 2007, Blood.
[22] Howell Sb. Resistance to apoptosis in prostate cancer cells. , 2000 .
[23] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[24] M. Loda,et al. Blood and tissue biomarkers in prostate cancer: state of the art. , 2010, The Urologic clinics of North America.
[25] A. Chakravarti,et al. Survivin mediates resistance to antiandrogen therapy in prostate cancer , 2005, Oncogene.
[26] Y. Sekine,et al. Gene expression of survivin and its spliced isoforms associated with proliferation and aggressive phenotypes of prostate cancer. , 2008, Urology.
[27] S. Mikolajczyk,et al. Are multiple markers the future of prostate cancer diagnostics? , 2004, Clinical biochemistry.
[28] S. Hatakeyama,et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. , 2007, Cancer research.
[29] J. Epstein,et al. A contemporary study correlating prostate needle biopsy and radical prostatectomy Gleason score. , 2008, The Journal of urology.
[30] H. El-Attar,et al. Comparison of serum survivin and alpha fetoprotein in Egyptian patients with hepatocellular carcinoma associated with hepatitis C viral infection. , 2010, Asian Pacific journal of cancer prevention : APJCP.
[31] A. Taille,et al. Urine biomarkers in prostate cancer , 2010, Nature Reviews Urology.
[32] Graça Raposo,et al. Exosomal-like vesicles are present in human blood plasma. , 2005, International immunology.
[33] Ryan M. Williams,et al. Novel biomarkers and therapeutic targets for prostate cancer. , 2010, Frontiers in bioscience.
[34] Y. Fradet. Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen , 2009, Current opinion in urology.
[35] Steven Piantadosi,et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. , 2003, The Journal of urology.
[36] S. Raab. A Contemporary Study Correlating Prostate Needle Biopsy and Radical Prostatectomy Gleason Score , 2009 .
[37] Alan W Partin,et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. , 2005, JAMA.
[38] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[39] X. Hao,et al. Knockdown of survivin expression by siRNAs enhances chemosensitivity of prostate cancer cells and attenuates its tumorigenicity. , 2009, Acta biochimica et biophysica Sinica.
[40] S. Fukuda,et al. Survivin, a cancer target with an emerging role in normal adult tissues , 2006, Molecular Cancer Therapeutics.
[41] A. Vickers,et al. Tumor markers in prostate cancer I: Blood-based markers , 2011, Acta oncologica.
[42] A. Jemal,et al. Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.
[43] Salma Khan,et al. Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential , 2009, British Journal of Cancer.
[44] H. Shiina,et al. Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis. , 2004, The Journal of urology.
[45] M. Mason,et al. Induction of heat shock proteins in B-cell exosomes , 2005, Journal of Cell Science.
[46] Guido Jenster,et al. Exosomes as biomarker treasure chests for prostate cancer. , 2011, European urology.
[47] G. Parmiani,et al. Tumor-released microvesicles as vehicles of immunosuppression. , 2007, Cancer research.